Russia's Sputnik Corona vaccine trials to begin in India

Clinical trials of the second and third phase of Russian corona vaccine Sputnik-V are expected to begin soon in India. For this, the Drug Controller General of India (DCGI) has approved the Indian drug manufacturer Dr. Reddy's Laboratories (DRL).

Permit for trials of Sputnik V:

On October 13, the Hyderabad-based pharmaceutical firm re-applied to the Drugs Controller General of India (DCGI) and sought approval for simultaneous human trials of the second and third phase of the Russian corona vaccine Sputnik-V in the country.

ALSO READ: Bengal achieves 99.9 pc rural household electrification

According to sources, the Subject Expert Committee (SEC) on Corona on Friday recommended to allow the second phase of the potential vaccine to be tested first after much deliberation. The second phase will allow human trials after submission of data related to the safety and immunity of the second phase.

Significantly, Sputnik V was tested in Russia on fewer people before it was registered as a vaccine, so DCGI questioned Dr Reddy's initial proposal of testing among a large population in India. But it is currently undergoing testing on 40,000 participants.

ALSO READ: Kerala’s Sabarimala Temple now open; Corona negative proof compulsory

Sputnik V vaccine has been developed jointly by RDIF and Gamalaya National Research Center of Epidemiology and Microbiology. Russia allowed Sputnik-V, the first vaccine of the corona virus, the first corona vaccine worldwide. After this, Russia has approved the second corona vaccine EpiVacCorona on 14 October.

In another report, WHO carried out a clinical trial of Remdesivir on 11,266 adult patients from 30 countries. It included four possible drug regimens including Remdesivir as well as hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon. Whose effects were evaluated.

In the study on Thursday, the WHO found that it did not affect the 28-day mortality or recovery of hospitalized patients with Covid-19. The details of the clinical trial are yet to be reviewed in detail. This primary study has been uploaded to the preprint server (medRxiv).

Stay tuned with the newstrack to get fastest updates. Click @englishnewstrack to follow us on Facebook and @newstrackmedia to follow on twitter.